Merck Overview
Merck operates in the areas of healthcare, life science and electronics, with around 58,000 employees in 66 countries. All three business sectors of Merck have R&D activities in Israel, and are actively promoting Sustainability in all areas. Inter-Lab - Mercks healthcare R&D center in Yavne. Inter-Lab can be credited with a great achievement in the pharmaceutical world; the development and production of the active ingredient in Rebif, an advanced treatment for multiple sclerosis. Currently the teams are involved in the development of novel antibody-based treatments for cancer and immuno-oncology therapies. Since 1996, Mercks biopharmaceutical sales and marketing activities in Israel are led by the team of Merck-Serono Ltd. in Herzliya. The Life Science business of Merck is represented in Israel by the acquired Sigma-Aldrich global company. R&D, production, sales and distribution activities operate in three state-of-the-art facilities, one in Rehovot and two in Jerusalem. Electronics R&D of semiconductor solutions is represented in Jerusalem at the Qlight site, while DS&S supplies specialty gases to Intel Kiryat Gat and other IL customers
Latest News
growth-neutral
LVMH: Share transactions disclosure
LVMH, a leading luxury goods company, disclosed its share transactions carried out from September 1st to September 5th, 2025. This disclosure was sent to the AMF on September 9th, 2025, and is publicly available on the companys website under the regulated information section. LVMH is represented in various sectors, including Wines and Spirits, Fashion and Leather Goods, Perfumes and Cosmetics, Watches and Jewelry, and Selective Retailing. The press release provides contact information for analysts, investors, and media across different regions, including France, Italy, the UK, the US, and China. The article does not indicate any significant impact on the companys growth or mention any specific financial transactions beyond the disclosure of share transactions.
growth-positive
מרק חתמה על הסכם שותפות אסטרטגית עם קרן ההון סיכון פרגרין, במסגרתו תצטרף לחממה הטכנולוגית אינסנטיב הפועלת בזיכיון רשות החדשנות
German pharmaceutical giant Merck has entered into a strategic partnership with Peregrine Ventures, joining the Incentive incubator managed by Lior Shachori. The incubator, based in Or Yehuda, specializes in life sciences technologies and will provide Merck with early access to startups in bio-convergence, pharma, and biotechnology fields. This partnership offers Merck opportunities for investment and support in development and clinical trials.
Partners
growth-positive
Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros | CTech
Israeli biotech firm Biolojic Design has entered into a collaboration agreement with pharmaceutical company Merck, potentially worth up to €346m. The deal will see Biolojic receive over €10m for the development of two molecules for potential cancer and immunological disorder drugs. Further funding will be provided as development progresses, with the full amount only being received if the drug reaches the market and generates sales. Biolojic, which uses AI to develop smart antibodies, also has a partnership with Teva for the development of asthma and eczema medications.
PartnersInvestment
growth-positive
Merck KGaA CEO: Israel has so much talent and ability
Merck Group CEO, Dr. Belén Garijo, aims to achieve annual revenue of €25 billion by 2025. Despite challenges such as inflation, trade wars, and government efforts to lower drug prices, Garijo believes the companys biggest challenge is managing change and providing a sense of security for employees. Merck Group, founded in 1668, is considered the oldest major chemical company in the world and has a market cap of about €20 billion. The company has stated it may make large acquisitions to grow, but Garijo believes the $25 billion target can be reached without these. Merck Group has three divisions: pharmaceuticals, chemicals for research and the life sciences industry, and chemicals for the electronics market.
CustomersPartnersAcquisitionManagement ChangesExpand
growth-positive
Larisa Amir appointed Managing Director of Merck R&D Center in Israel CTech
Larisa Amir has been appointed as the Managing Director of Merck KGaA Healthcare R&D Center in Israel. She will be responsible for managing the center and promoting research and development, with a focus on in-house innovation and external scouting for technologies and biotechnology capabilities in Israeli startups, academia, and hospitals. Amir has extensive experience in the biotech industry and holds an M.Sc. in Biotechnology and an MBA.
Management Changes
Team Members
6
Employees: 201-500
Web & Social Links
| Website | www.merckgroup.com/en/worldwide/merck-in-israel.html |
Locations
Ha-Kishon St 18, Yavne, Israel
Hebrew University/Edmond J. Safra Campus Giv'at Ra, Jerusalem, Israel
Maskit Street 25, Herzliya, Israel
3 Plaut st., Park Rabin, Rehovot, Israel
64 Darmstadt, Germany
Photos & Videos
1 item(s)
Merck Business
Business models
—
Product stage
—
Employees
201-500
Sector
—Target Customer
—Core Technology
—Tags (12)
innovation-centeroncologyneurologyfertilitysemiconductorselectronicsimmunologynanotechnologymaterialslife-sciencespharmaceuticalshealthcareMerck Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Public Offering / Exit
MNAEvent
Jun 2015
Undisclosed
Merck Lifecycle
All Events
MNAEvent
Jun 2015
Undisclosed
Merck News
13 articles
growth-neutral
LVMH: Share transactions disclosure
LVMH, a leading luxury goods company, disclosed its share transactions carried out from September 1st to September 5th, 2025. This disclosure was sent to the AMF on September 9th, 2025, and is publicly available on the companys website under the regulated information section. LVMH is represented in various sectors, including Wines and Spirits, Fashion and Leather Goods, Perfumes and Cosmetics, Watches and Jewelry, and Selective Retailing. The press release provides contact information for analysts, investors, and media across different regions, including France, Italy, the UK, the US, and China. The article does not indicate any significant impact on the companys growth or mention any specific financial transactions beyond the disclosure of share transactions.
growth-positive
מרק חתמה על הסכם שותפות אסטרטגית עם קרן ההון סיכון פרגרין, במסגרתו תצטרף לחממה הטכנולוגית אינסנטיב הפועלת בזיכיון רשות החדשנות
German pharmaceutical giant Merck has entered into a strategic partnership with Peregrine Ventures, joining the Incentive incubator managed by Lior Shachori. The incubator, based in Or Yehuda, specializes in life sciences technologies and will provide Merck with early access to startups in bio-convergence, pharma, and biotechnology fields. This partnership offers Merck opportunities for investment and support in development and clinical trials.
Partners
growth-positive
Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros | CTech
Israeli biotech firm Biolojic Design has entered into a collaboration agreement with pharmaceutical company Merck, potentially worth up to €346m. The deal will see Biolojic receive over €10m for the development of two molecules for potential cancer and immunological disorder drugs. Further funding will be provided as development progresses, with the full amount only being received if the drug reaches the market and generates sales. Biolojic, which uses AI to develop smart antibodies, also has a partnership with Teva for the development of asthma and eczema medications.
PartnersInvestment
growth-positive
Merck KGaA CEO: Israel has so much talent and ability
Merck Group CEO, Dr. Belén Garijo, aims to achieve annual revenue of €25 billion by 2025. Despite challenges such as inflation, trade wars, and government efforts to lower drug prices, Garijo believes the companys biggest challenge is managing change and providing a sense of security for employees. Merck Group, founded in 1668, is considered the oldest major chemical company in the world and has a market cap of about €20 billion. The company has stated it may make large acquisitions to grow, but Garijo believes the $25 billion target can be reached without these. Merck Group has three divisions: pharmaceuticals, chemicals for research and the life sciences industry, and chemicals for the electronics market.
CustomersPartnersAcquisitionManagement ChangesExpand
growth-positive
Larisa Amir appointed Managing Director of Merck R&D Center in Israel CTech
Larisa Amir has been appointed as the Managing Director of Merck KGaA Healthcare R&D Center in Israel. She will be responsible for managing the center and promoting research and development, with a focus on in-house innovation and external scouting for technologies and biotechnology capabilities in Israeli startups, academia, and hospitals. Amir has extensive experience in the biotech industry and holds an M.Sc. in Biotechnology and an MBA.
Management Changes
Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million Merck
Startup from Merck Innovation Lab in Israel Markets First Predictive Maintenance Sensors Merck
growth-positive
German drugmaker Merck sets up Israel incubator to tap into chip, sensor tech
German pharmaceutical and chemicals firm Merck has launched its newest incubator in Israel called PMatX. The incubator will support Israeli startup companies specializing in advanced electronic products, including semiconductors and sensor technologies. Merck, with 52,000 employees globally and total sales of €15 billion in 2017, aims to invest in groundbreaking technologies that lead to a paradigm shift in how business is done. The new incubator, set up in Yavne, Israel, will run a budget of about €20 million over three years and will focus on semiconductor and display crystal technologies. Merck previously set up a healthcare and life science incubator, BioIncubator, in Israel in 2011.
PartnersInvestment
growth-positive
Merck sets up €20m fund for Israeli biotech cos
German pharmaceutical company Merck has announced the founding of the ExploreBio pre-seed fund to invest €20 million in young biotechnology companies over the next five years. Merck is setting up the fund in cooperation with Arkin Bio Ventures, Pontifax Fund, and China-based international company WuXi Apptec. The fund will invest in companies that are in initial trials for proving feasibility. Merck already operates two technology incubators in Israel. Merck, founded in 1668, is the worlds oldest drug and chemical company, with business in health, biology research, and materials.
InvestmentPartners
growth-positive
Merck KGaA Sets Up PMatX Incubator in Israel for Next-Generation Electronics
Merck KGaA has announced the creation of a technology innovation laboratory called PMatX in Israel. The laboratory will serve as an incubator for start-up companies in the field of next-generation electronics. The program will be supported by partners such as HP and Battery Ventures, and will be funded with an overall investment of approximately €20 million. The incubator will be located at Merck KGaAs R&D site in Yavne, Israel, and will focus on start-ups in the Performance Materials business sector. The first companies are expected to join the program in the fourth quarter of 2017.
Investment
growth-positive
Merck extends Weizmann Institute partnership
Merck KGaA has extended its partnership with Israels Weizmann Institute of Science by signing a new framework agreement. The agreement will focus on research collaboration and licensing in the fields of immuno-oncology, immunology, and oncology. Merck will fund each of the two research areas with up to �1 million per year over the three-year period initially. The partnership aims to deliver new solutions to respond to unmet medical needs. Merck has a long-standing relationship with the Weizmann Institute, dating back to 1978. The company employs over 300 people in Israel and has sites in Yavne, Herzliya, Rehovot, and Jerusalem.
Partners
growth-positive
Merck CEO sees firm's future intertwined with Israel's
Merck, a multinational chemical and technology company, announced its acquisition of Israeli start-up Qlight Nanotech. The acquisition will enhance Mercks position as a market leader in liquid crystal display technology. Merck has a strong connection with Israel and has been active there since 1978. The company plans to expand its presence in Israel with the addition of Qlights Jerusalem location. Merck also has partnerships with Israeli research institutions and runs a biotech incubator for early-stage firms. The acquisition of Qlight will allow Merck to further expand its business portfolio and explore new opportunities in industries outside the drug business. Merck sees Israel as a rich source of technology in areas such as big data, cyber-security, robotics, machine vision, and materials technology.
AcquisitionPartners
growth-positive
Merck Serono opens Israeli drug development incubator
Merck Serono has inaugurated its new drug development incubator in Israel, investing �10 million in the project. The incubator, located at Inter-Lab Incubator in Yavne, will finance and support companies in the field of drug discovery and development. Merck Serono will fully finance some companies and finance others in collaboration with partners, such as venture capital funds. The company is particularly interested in oncology, fertility, multiple sclerosis, and endocrinology. The incubator is the first of its kind for Merck Serono and is part of the companys strategy for innovation and collaboration in the pharmaceutical industry. The chairman of Merck KGaA, Dr. Karl-Ludwig Kley, has been a strong supporter of Israels pharmaceutical industry and has emphasized the importance of collaborations with Israeli companies.
InvestmentPartners
Merck Team
Regine Shevach
Country Speaker & Managing Director of Merck Electronic Activities in Israel
Guy Nir
Israel Operation and Services Manager, Versum Materials
Employee Info
| Employees (range) | 201-500 |
| Exact count | 400 |
| Team members | 7 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Merck Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-08-25 10:56:57.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-22 06:38:43.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:22:22.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:10:54.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:22:22.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-08-25 11:05:41.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:12:31.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:08:28.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:22:13.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-01-22 08:07:12.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:40:12.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:08:28.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:19:05.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2022-08-25 10:56:57.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:10:54.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:19:18.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:22:22.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:09:11.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:20:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:19:46.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-06-02 12:17:10.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Paz Eliav
· paze@cet.ac.il · Manual · 2016-04-05 13:14:55.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 77/100 |
| Missing | product stage, sector, founding month, business model, funding rounds, markets |
| BI Verification | Yamila Silbert |
| Crunchbase | merck-kgaa |
| Phone | +97299510737 |
| Creator | Paz Eliav |
| Creator email | paze@cet.ac.il |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2023-06-02T00:00:00.000Z |
| Created | 2016-04-05T00:00:00.000Z |
| Status detail | Public on FWB on Oct, 1995; |